Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Eudragit RS PO Nanoparticles For Sustained Release Of Pyridostigmine Bromide

F. Hoobakht, F. Ganji, E. Vasheghani-Farahani, S. M. Mousavi
Published 2013 · Materials Science

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Pyridostigmine bromide (PB) is an inhibitor of cholinesterase, which is used in the treatment of myasthenia gravis and administered for protection against exposure to toxic nerve agents. Tests were done to investigate prolonging the half-life of PB and improving its release behavior. PB was loaded in nanoparticles (NPs) of Eudragit RS PO (Eu-RS) prepared using the technique of quasi emulsion solvent diffusion. Variables of output power of the sonicator, bath temperature and mixing time, were chosen as the optimization factors to obtain the minimum sized NPs. In addition, emulsions were tested at different ratios of drug-to-polymer by dynamic light scattering to determine size and zeta potential of NPs. UV-spectroscopy was used to determine PB content of the NPs. Drug-loaded NPs were characterized by scanning electron microscopy, X-ray diffraction, and Fourier transform infrared spectra. Results determined that mixing time had a significant impact on the size of Eu-RS NPs, but power output of sonicator and bath temperature had no significant effect. The particle size obtained at the optimum condition (power output of 70 W, bath temperature of 33 °C, and mixing time of 7 min) was less than 200 nm (optimum sizes were 138.9 and 179.5 nm for Eu-RS and PB-loaded Eu-RS NPs, respectively). The optimum PB-loaded Eu-RS NPs at the PB to Eu-RS weight ratio of 1–4 and 20 % of loaded PB released from the nanocarriers within 100 h.
This paper references
10.1080/03639040701377334
Formulation Design of an HPMC-Based Sustained Release Tablet for Pyridostigmine Bromide as a Highly Hygroscopic Model Drug and its In Vivo/In Vitro Dissolution Properties
Yuh-Tyng Huang (2007)
10.1016/J.IJPHARM.2006.01.041
Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles.
K. Dillen (2006)
10.18433/J3SW2T
Preparation and Physicochemical Characterization of Eudragit ® RL100 Nanosuspension with potential for Ocular Delivery of Sulfacetamide
B. Mandal (2010)
10.1016/j.clineuro.2010.06.018
Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: Results of a prospective multicenter open-label trial
J. Sieb (2010)
10.1016/j.jhazmat.2011.09.052
Optimization of petroleum refinery effluent treatment in a UASB reactor using response surface methodology.
S. O. Rastegar (2011)
10.1007/s12272-012-0313-6
Role of a novel pyridostigmine bromide-phospholipid nanocomplex in improving oral bioavailability
Q. Tan (2012)
10.1016/j.neulet.2007.02.019
An investigation of acetylcholine released in skeletal muscle and protein unbound drug released in blood based on the pyridostigmine bromide (pretreatment drug) sustained-release pellets by microdialysis technique in the rabbit model
Yuh-Tyng Huang (2007)
10.1002/JPS.2600780118
Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method.
Y. Kawashima (1989)
Preparation and characterization of poly(lactic acid) nanoparticles for sustained release of pyridostigmine bromide.
Q. Tan (2012)
10.1016/S0168-3659(02)00127-X
Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake.
S. Sahoo (2002)
10.1016/S0928-0987(02)00057-X
Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen.
R. Pignatello (2002)
10.1016/S0378-5173(02)00146-1
Preparation and in vitro evaluation of pyridostigmine bromide microparticles.
N. Hegazy (2002)
10.1016/S0378-5173(03)00209-6
Preparation of sustained-release nitrendipine microspheres with Eudragit RS and Aerosil using quasi-emulsion solvent diffusion method.
M. S. Yang (2003)
10.1016/j.ijpharm.2011.11.020
Drug delivery by polymeric nanoparticles induces autophagy in macrophages.
H. Eidi (2012)
10.5897/AJPP12.025
Evaluation and optimization of factors affecting novel diclofenac sodium-eudragit RS100 nanoparticles
Khosro Adibkia (2012)
Prolonged release matrix tablet of pyridostigmine bromide: formulation and optimization using statistical methods.
N. Bolourchian (2012)
10.1002/JPS.10227
Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery.
R. Pignatello (2002)
10.1080/03639040601031890
Formulation Design of a Highly Hygroscopic Drug (Pyridostigmine Bromide) for its Hygroscopic Character Improvement and Investigation of In Vitro/In Vivo Dissolution Properties
Yuh-Tyng Huang (2007)
10.1016/j.colsurfb.2010.11.014
Naproxen-eudragit RS100 nanoparticles: preparation and physicochemical characterization.
Khosro Adibkia (2011)
10.1007/s11095-005-2496-8
Lyophilized Paclitaxel Magnetoliposomes as a Potential Drug Delivery System for Breast Carcinoma via Parenteral Administration: In Vitro and in Vivo Studies
J. Zhang (2005)
10.1016/j.ejpb.2009.02.013
The use of Eudragit RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione.
A. Lopedota (2009)
10.1016/j.ijpharm.2009.09.036
Characterization, stabilization and activity of uricase loaded in lipid vesicles.
Q. Tan (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar